Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Dr. David J. Brailer elected independent director, effective November 3, 2026, through Teva’s 2027 annual meeting.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. David J. Brailer elected independent director, effective November 3, 2026, through Teva’s 2027 annual meeting
- Expected committee assignments: Human Resources and Compensation, Compliance
- Health-tech and healthcare policy expertise adds strategic perspective to Teva’s board
- Standard non-executive director compensation, with no disclosed related-party interests or election arrangements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.